Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 December 2021 Photo Supplied
For Dr Katleho Tsilo, one of the latest graduates from the University of the Free State (UFS) Faculty of Health Sciences says graduating from medical school is a dream come true for her and her family.

For Dr Katleho Tsilo, one of the newest graduates from the University of the Free State (UFS) Faculty of Health Sciences, graduating from medical school does not only represent the answered prayers, persistence and sheer grace, it is also a dream come true for her and her family.

Dr Tsilo graduated on Monday 13 December 2021 during the UFS’ year-end graduating ceremonies. 

“It still feels unreal that I was able to overcome the greatest challenge that I was presented with. In my entire medical school career, I have faced many great challenges, from not having any kind of funding at all, to initially not being accepted into medicine to really having to fight for my position each and every semester while also fighting with and for my fellow students in the various leadership positions aforementioned. 

“There were moments of weakness where I wished to just quit it all, but with support from the faculty and my family, I managed to hold on. My dream was and still is bigger that any challenge that I have ever encountered,” says Dr Tsilo. 

Had various leadership positions

During her student years, this Botshabelo native engaged in various leadership positions. She also had to overcome numerous obstacles including the imposter syndrome. According to her, coming from a poor background, with very little resources, she sometimes felt insecure about what she could offer and what she is capable of. Being a health worker during the COVID-19 pandemic was also very challenging because of the uncertainty of everything and how dangerous the work environment in the hospital was proving to be.

“I was privileged enough to be elected as part of the MSA (Medical Students Association) in the Academics portfolio, this is where I then came up with the idea of collecting textbook donations and gifting the less privileged students. I was also elected to be part of the Residence Committee of the new Health Sciences Residence, in the Finance Portfolio.”

Can’t imagine doing anything else

Though she did not always want to study medicine, she ultimately decided on this field as she could not imagine doing anything else. She believes it is a calling, as she always wanted to live a life full of purpose and helping other people. Helping put a smile on someone’s face when they are going through illness is enough to change one’s life, explains Dr Tsilo about her decision to study medicine. She will be doing her internship at the Leratong Hospital in Krugersdorp, Gauteng.

Dr Tsilo, who is hoping to go into Health Science Education or Public Health, says her motivation comes from her family background. “Having been surrounded by poverty for the greater part of my life pushed me to become the difference. I was and still am determined to not be another statistic. Another thing that really motivates me is being of some help to someone. I cannot change the whole world at one time but I can surely start with one person at a time. I believe so much in the power of giving, whether knowledge, time or resources So much that I started my own foundation: the Open Hands Foundation.”

According to Dr Tsilo, her journey to graduating was intimidating – having to adjust to being a student was already tough, however adjusting to being a medical student proved to be a whole new level of challenging. It came with a lot of late nights and very early mornings, months without seeing her family and having almost no luxurious pastimes. 

But she persevered because she always had a goal and was determined to reach it. She had a vision to complete this degree and do it in record time and that’s exactly what she did. “Your vision should always fuel your mission,” says Dr Tsilo. 

Besides medicine, her other passions include charity work – something she has been doing right through her student years. 

Passion for charity work 

“I love charity work and if you did not find me studying, that’s what you would find me, doing. Open Hands is where I exercise this passion. I collect clothes, shoes and food items for the less privileged in our communities.
To students struggling and also facing difficulties, I have this simple message: Don’t stop. Don’t stop working hard, don’t stop hoping and dreaming and if you need help of any kind, it is always available. Know that you are not struggling alone, struggle is part of the journey – it always seems impossible but as long as you don’t stop you will eventually reach your destination.”

Prof Lynette van der Merwe, who took up her new position as Academic Head in the Division Health Sciences Education, Faculty of Health Sciences on 1 December 2021, congratulated the new cohort of UFS doctors and reminded them of the three Cs in the MBChB programme in 2021 – courage, conviction and compassion. She also proposed a new “C” for the year ahead: Character.  

“Character is seen in how you treat those who can do nothing for you. It takes time to develop, and only grows through suffering and failing; no shortcuts, no life hacks here. Character makes you seek to be worth knowing, rather than well known. Adam Grant says: ‘Meaning is about making a difference, not having an audience. Your legacy is not how many footprints you leave.  It’s how long they last.’ Wherever life takes you from here, whatever happens to you or through you, do what is right, not easy. Be a person of value, not success.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept